Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Issue Archive

Table of Contents

EDITORIAL

CLINICAL GUIDELINES

EXCEPTIONAL CASE REPORT

REVIEW ARTICLES

CLINICAL TRIALS AND OBSERVATIONS

Stephanie Guidez,on behalf of the French Innovative Leukemia Organization (FILO) CLL group,Julien Labreuche,on behalf of the French Innovative Leukemia Organization (FILO) CLL group,Elodie Drumez,on behalf of the French Innovative Leukemia Organization (FILO) CLL group,Loic Ysebaert,on behalf of the French Innovative Leukemia Organization (FILO) CLL group,Jana Bakala,on behalf of the French Innovative Leukemia Organization (FILO) CLL group,Caroline Delette,on behalf of the French Innovative Leukemia Organization (FILO) CLL group,Bénédicte Hivert,on behalf of the French Innovative Leukemia Organization (FILO) CLL group,Caroline Protin,on behalf of the French Innovative Leukemia Organization (FILO) CLL group,Hervé Declercq,on behalf of the French Innovative Leukemia Organization (FILO) CLL group,Mélanie Verlay,on behalf of the French Innovative Leukemia Organization (FILO) CLL group,Jean Pierre Marolleau,on behalf of the French Innovative Leukemia Organization (FILO) CLL group,Alain Duhamel,on behalf of the French Innovative Leukemia Organization (FILO) CLL group,Pierre Morel,on behalf of the French Innovative Leukemia Organization (FILO) CLL group

IMMUNOBIOLOGY AND IMMUNOTHERAPY

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

THROMBOSIS AND HEMOSTASIS

GLOBAL ADVANCES

COMMENTARY

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals